Britain and America have agreed to a key bilateral deal that will keep no duties on British drug shipments being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to raise expenditure on medicines through the public health system. This move ensures that duties on these vital goods will remain at zero for a duration of the next three years.
This agreement follows previous threats to significantly raise import taxes on branded drug products, with potential rates discussed reaching 100%.
"This arrangement with the Britain reinforces the global environment for innovative medicines and brings long-overdue fairness to American-British pharmaceutical trade," a release declared.
Trade Impact
Pharmaceuticals are one of the the United Kingdom's largest export categories to the US, which is easily the biggest buyer for major British pharmaceutical firms.
Trade data reveal that in the year to the end of the third quarter, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This figure accounted for nearly one-fifth of all goods exports in that span.
"This deal secures work, increases investment and paves the way for the UK to emerge as a global hub for medical research," a minister remarked.
Specific NHS Changes
The agreement entails several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a goal to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must return to the NHS to stay within budget will be capped at fifteen percent. Previously, refunds were more than twenty percent.
Industry Background
The pact follows a protracted row between the sector and the ministers over medicine costs and regulatory access.
This friction were exacerbated by assertions that US consumers were charged several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
